Atlas Trials

Candonilimab in Combination With LM-302 for Claudin 18.2 Positive-advanced Biliary Tract Cancer After Failure of Standard of Chemotherapy and PD1/PD-L1 Antibody

Clinical trial NCT05994001 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05994001
Sponsor
Shanghai Zhongshan Hospital
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Biliary Tract CancerCandonilimabClaudin 18.2
Start date
2023-08-01
Primary completion
2026-05-01
Enrollment
78

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.